AstraZeneca's Crestor to challenge Pfizer's Lipitor In Korea
Published: 2004-05-31 06:59:00
Updated: 2004-05-31 06:59:00
AstraZeneca's Crestor (rosuvastatin), which is expected to be launched during the first half of this year, will race to catch up Korea's market share, posing a threat to Pifzer's Lipitor (atorvastatin) in the antihyperlipemic market.
Market analysts project that competition between foreign-inv...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
